Halozyme Therapeutics, Inc. $HALO Stock: Nisa Investment Advisors LLC Raises Stake

Nisa Investment Advisors LLC lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 640.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,512 shares of the biopharmaceutical company’s stock after purchasing an additional 21,202 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Congress Asset Management Co. boosted its position in shares of Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the period. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the 2nd quarter worth $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth $196,540,000. Royal London Asset Management Ltd. boosted its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after buying an additional 200,262 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth $105,570,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $125.63 on Friday. The company has a fifty day moving average of $111.37 and a two-hundred day moving average of $87.03. The company has a market capitalization of $14.26 billion, a PE ratio of 37.50, a P/E/G ratio of 0.47 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $126.23. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, TD Cowen boosted their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.55.

Insiders Place Their Bets

In related news, Director Matthew L. Posard sold 18,996 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. The trade was a 24.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 over the last 90 days. 2.50% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.